Eli Lilly Treatment For Crohn's Tops Placebo In Latest Study, Makes Plans For 2024
Portfolio Pulse from Vandana Singh
Eli Lilly plans to submit a marketing application for its Crohn's disease drug, mirikizumab, to the FDA in 2024. The drug met all major secondary endpoints in the VIVID-1 Phase 3 study, outperforming the placebo. The trial also included Johnson & Johnson's Stelara as an active control. Mirikizumab demonstrated non-inferiority versus ustekinumab, but did not achieve superiority.
October 12, 2023 | 2:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's mirikizumab met all major secondary endpoints in a Phase 3 study, outperforming the placebo. The company plans to submit a marketing application to the FDA in 2024.
The successful trial results for mirikizumab and the planned FDA submission could potentially lead to a new revenue stream for Eli Lilly, positively impacting its stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Johnson & Johnson's Stelara was used as an active control in the VIVID-1 Phase 3 study of Eli Lilly's mirikizumab.
While Johnson & Johnson's Stelara was used as an active control in the study, the news does not directly impact the company or its stock as it does not pertain to Stelara's efficacy or market position.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50